Compare PubMatic Inc (PUBM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs GeneDx Holdings Corp — how do they compare? PubMatic Inc trades at $16.19 (market cap $742.01M), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: GeneDx Holdings Corp is far larger — about 3.5× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| PUBM | WGS | |
|---|---|---|
Market Cap | $742.01M | $2.56B |
Sector | Technology | Technology |
52-Week High | $17.78 | $167.51 |
52-Week Low | $6.28 | $34.51 |
Enterprise Value | $645.14M | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PubMatic (PUBM) trades at $16.29, down 1.27% on the day, with a bullish technical signal driven by moving averages and recent support above the 20-day average. The company reported Q2 2026 revenue growth of 11% year-over-year and an EPS beat, though net income margins remain negative. Positive sentiment is fueled by AI-driven ad tech adoption and strategic hires, such as the new Global Chief Revenue Officer.
Outlook: Strong analyst consensus (64.7% buy ratings) and a $20.83 price target suggest upside potential from AI product momentum and cost controls. Risks include persistent profitability challenges and CFO transition uncertainty. The stock offers growth exposure but requires monitoring of margin improvement.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
